Eli Lilly (NYSE:LLY) enters today’s market discussion as sector themes, operations, and broader conditions draw attention.

Eli Lilly and Co.‘s CEO Dave Ricks announced a significant increase in the use of GLP-1 treatments among seniors, following Medicare’s July decision to cover obesity drugs. On Monday, Ricks said in an interview with CNBC that 70% of the...

Eli Lilly (NYSE: LLY) has started construction on a US$6.5b manufacturing facility in Houston to produce its oral GLP-1 drug Foundayo. The new site is focused on supplying Foundayo for obesity treatment as demand for oral GLP-1 therapies grows in the US and abroad. The project includes partnerships for local workforce training in Houston to support specialized pharmaceutical manufacturing roles. This large Houston buildout for Foundayo is an important piece to weigh alongside the rest of our...

Eli Lilly and Company has broken ground on a $6.5 billion manufacturing facility in Houston, Texas, marking another milestone in the pharmaceutical company's $50 billion initiative to expand domestic medicine production. The facility is one of 10 U.S. manufacturing sites Lilly has announced since 2020 and will produce active pharmaceutical ingredients (APIs) for Foundayo (orforglipron), the company's first synthetic oral GLP-1 medicine, alongside other small-molecule medicines and advanced therapeutics.

With a trillion-dollar market cap and a wildly successful GLP-1 portfolio, Eli Lilly isn’t resting on its laurels. At the Psych Congress 2026, the company presented early-stage data that could support the potential of its next-gen GLP-1 and GIP receptor agonist to treat diseases far beyond obesity.

Ken Langone built a fortune betting on Home Depot decades before anyone called it a sure thing, and now he says another stock in his portfolio is giving it a serious run for the top spot.

Eli Lilly and Company broke ground this week in Houston, Texas.

HOUSTON – (Realty News Report) – Eli Lilly and Company broke ground on a $6.5 billion active pharmaceutical ingredient manufacturing facility in Eli Lilly Breaks Ground on Houston Plant

About 700,000 seniors have started GLP-1 treatments since Medicare coverage began in July.

Twist Bioscience Corporation (NASDAQ:TWST) is on the cusp of gaining significant exposure to the rapidly evolving artificial intelligence (AI)-driven drug discovery ecosystem.

Eli Lilly and Co. stock closed at USD 1,164.89 on September 21, 2026, up 1.04 percent. Foundayo gene